A Randomized, Open-Label, Six-Sequence, Three-Period Crossover Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER Plus CSG452 in Healthy Adult Volunteers, and to Characterize the Food Effect on the Pharmacokinetics of K-001
Latest Information Update: 05 Jun 2023
At a glance
- Drugs K 001 (Primary) ; Pemafibrate (Primary) ; Tofogliflozin (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics
Most Recent Events
- 01 Jun 2023 Status changed from recruiting to completed.
- 21 Feb 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 24 Feb 2023 to 23 Feb 2023.
- 21 Feb 2023 Status changed from not yet recruiting to recruiting.